Holdco Nuvo Group D.G Ltd
Holdco Nuvo Group D.G Ltd engages in the research, development, and marketing of medical devices for pregnancy monitoring in Israel, the United States, and internationally. It provides INVU platform, a remote pregnancy monitoring platform that provides expectant mothers with a self -administered wireless sensory band, which enables them and their obstetricians to monitor maternal and fetal heart … Read more
Holdco Nuvo Group D.G Ltd (NUVOQ) - Net Assets
Latest net assets as of December 2023: $-67.49 Million USD
Based on the latest financial reports, Holdco Nuvo Group D.G Ltd (NUVOQ) has net assets worth $-67.49 Million USD as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.49 Million) and total liabilities ($70.98 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-67.49 Million |
| % of Total Assets | -1936.03% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Holdco Nuvo Group D.G Ltd - Net Assets Trend (2021–2023)
This chart illustrates how Holdco Nuvo Group D.G Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Holdco Nuvo Group D.G Ltd (2021–2023)
The table below shows the annual net assets of Holdco Nuvo Group D.G Ltd from 2021 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-67.49 Million | -74.37% |
| 2022-12-31 | $-38.70 Million | -49.79% |
| 2021-12-31 | $-25.84 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Holdco Nuvo Group D.G Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5433400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $76.28 Million | % |
| Total Equity | $-67.49 Million | 100.00% |
Holdco Nuvo Group D.G Ltd Competitors by Market Cap
The table below lists competitors of Holdco Nuvo Group D.G Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
UNITED BASALT PRODUCTS LTD
SEM:UBP
|
$9.93K |
|
Nevo Energy Inc
PINK:NEVE
|
$9.93K |
|
CVC Income & Growth Limited
LSE:CVCE
|
$9.94K |
|
Strix Group Plc
LSE:KETL
|
$9.95K |
|
RPAD5F
SA:RPAD5F
|
$9.92K |
|
47HA
LSE:47HA
|
$9.91K |
|
Esrey Resources Ltd
PINK:LNGYF
|
$9.91K |
|
UNITED LABELS - Dusseldorf Stock Exchang
DU:ULC
|
$9.91K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Holdco Nuvo Group D.G Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -38,704,000 to -67,490,000, a change of -28,786,000.
- Net loss of 33,655,000 reduced equity.
- New share issuances of 13,000,000 increased equity.
- Other factors decreased equity by 8,131,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-33.66 Million | -49.87% |
| Share Issuances | $13.00 Million | +19.26% |
| Other Changes | $-8.13 Million | -12.05% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Holdco Nuvo Group D.G Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | $-0.78 | $0.00 | x |
| 2022-12-31 | $-1.17 | $0.00 | x |
| 2023-12-31 | $-2.04 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Holdco Nuvo Group D.G Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -19122.16%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-31.93 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.81 Million |
| 2023 | 0.00% | -19122.16% | 0.05x | 0.00x | $-26.91 Million |
Industry Comparison
This section compares Holdco Nuvo Group D.G Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Holdco Nuvo Group D.G Ltd (NUVOQ) | $-67.49 Million | 0.00% | N/A | $9.93K |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |